Cochrane · systematic review · CD012723
Treatment for telangiectasias and reticular veins
Nakano, LCU, Cacione, DG, Baptista-Silva, JCC, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
VascularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
70
current version
GRADE rated
40
No studies
30
Included studies
NR
No studies 30 · 42.9%Ungraded 0 · 0%Very low 0 · 0%Low 16 · 22.9%Moderate 24 · 34.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Sclerotherapy compared to placebo for treatment of telangiectasias and reticular veins
Population: people with telangiectasias and reticular veins
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Resolution or improvement of telangiectasias ( Sclerotherapy vs placebo | no estimate extracted | 4 studies · 613 participants | Moderate Downgraded: inconsistency |
Adverse events ‐ hyperpigmentation ( Sclerotherapy vs placebo | RR 11.88 [4.54, 31.09] | 3 studies · 528 participants | Moderate Downgraded: imprecision, inconsistency |
Adverse events ‐ matting ( Sclerotherapy vs placebo | RR 4.06 [1.28, 12.84] | 3 studies · 528 participants | Moderate Downgraded: imprecision, inconsistency |
Pain ( Sclerotherapy vs placebo | no estimate extracted | 1 study · 40 participants | Low Downgraded: inconsistency |
Recurrence Sclerotherapy vs placebo | no estimate extracted | NR | No studies |
Time to resolution Sclerotherapy vs placebo | no estimate extracted | NR | No studies |
Quality of life Sclerotherapy vs placebo | no estimate extracted | NR | No studies |
Sclerotherapy (polidocanol) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins
Population: people with telangiectasias and reticular veins
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Resolution or improvement of telangiectasias ( Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant) | no estimate extracted | 7 studies · 852 participants | Moderate Downgraded: imprecision |
Adverse events ‐ hyperpigmentation ( Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant) | RR 0.94 [0.62, 1.43] | 6 studies · 819 participants | Moderate Downgraded: imprecision |
Adverse events ‐ matting ( Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant) | RR 0.82 [0.52, 1.27] | 7 studies · 859 participants | Moderate Downgraded: imprecision |
Pain ( Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant) | no estimate extracted | 5 studies · 480 participants | Moderate Downgraded: imprecision |
Recurrence Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant) | no estimate extracted | NR | No studies |
Time to resolution Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant) | no estimate extracted | NR | No studies |
Quality of life Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant) | no estimate extracted | NR | No studies |
Sclerotherapy (STS) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins
Population: people with telangiectasias and reticular veins
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Resolution or improvement of telangiectasias ( Sclerotherapy (STS) vs sclerotherapy (any sclerosant) | no estimate extracted | 4 studies · 473 participants | Moderate Downgraded: imprecision |
Adverse events ‐ hyperpigmentation ( Sclerotherapy (STS) vs sclerotherapy (any sclerosant) | RR 1.71 [1.1, 2.64] | 4 studies · 478 participants | Moderate Downgraded: imprecision |
Adverse events ‐ matting ( Sclerotherapy (STS) vs sclerotherapy (any sclerosant) | RR 2.1 [1.14, 3.85] | 2 studies · 323 participants | Moderate Downgraded: imprecision |
Pain ( Sclerotherapy (STS) vs sclerotherapy (any sclerosant) | RR 1.49 [0.99, 2.25] | 4 studies · 409 participants | Moderate Downgraded: imprecision |
Recurrence Sclerotherapy (STS) vs sclerotherapy (any sclerosant) | no estimate extracted | NR | No studies |
Time to resolution Sclerotherapy (STS) vs sclerotherapy (any sclerosant) | no estimate extracted | NR | No studies |
Quality of life Sclerotherapy (STS) vs sclerotherapy (any sclerosant) | no estimate extracted | NR | No studies |
Sclerotherapy (hypertonic saline) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins
Population: people with telangiectasias and reticular veins
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Resolution or improvement of telangiectasias ( Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant) | no estimate extracted | 3 studies · 348 participants | Moderate Downgraded: risk of bias |
Adverse events ‐ hyperpigmentation ( Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant) | RR 0.74 [0.59, 0.93] | 2 studies · 288 participants | Moderate Downgraded: imprecision |
Adverse events ‐ matting ( Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant) | RR 0.89 [0.58, 1.36] | 2 studies · 288 participants | Moderate Downgraded: imprecision |
Pain ( Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant) | no estimate extracted | 3 studies · 348 participants | Moderate Downgraded: inconsistency |
Recurrence Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant) | no estimate extracted | NR | No studies |
Time to resolution Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant) | no estimate extracted | NR | No studies |
Quality of life Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant) | no estimate extracted | NR | No studies |
Sclerotherapy (chromated glycerin) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins
Population: people with telangiectasias and reticular veins
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Resolution or improvement of telangiectasias ( Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant) | no estimate extracted | 2 studies · 125 participants | Low |
Adverse events ‐ hyperpigmentation ( Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant) | RR 0.49 [0.09, 2.5] | 2 studies · 125 participants | Low |
Adverse events ‐ matting ( Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant) | RR 0.31 [0.01, 7.53] | 1 study · 99 participants | Low |
Pain ( Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant) | RR 1.5 [0.3, 7.55] | 1 study · 26 participants | Low |
Recurrence Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant) | no estimate extracted | NR | No studies |
Time to resolution Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant) | no estimate extracted | NR | No studies |
Quality of life Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant) | no estimate extracted | NR | No studies |
Foam compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins
Population: people with telangiectasias and reticular veins
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Resolution or improvement of telangiectasias ( Foam vs sclerotherapy (any sclerosant) | no estimate extracted | 2 studies · 187 participants | Low Downgraded: imprecision |
Adverse events ‐ hyperpigmentation ( Foam vs sclerotherapy (any sclerosant) | RR 2.12 [0.44, 10.23] | 2 studies · 187 participants | Low Downgraded: imprecision |
Adverse events ‐ matting ( Foam vs sclerotherapy (any sclerosant) | RR 6.12 [1.04, 35.98] | 2 studies · 187 participants | Low Downgraded: imprecision |
Pain ( Foam vs sclerotherapy (any sclerosant) | no estimate extracted | 1 study · 147 participants | Low Downgraded: imprecision |
Recurrence Foam vs sclerotherapy (any sclerosant) | no estimate extracted | NR | No studies |
Time to resolution Foam vs sclerotherapy (any sclerosant) | no estimate extracted | NR | No studies |
Quality of life Foam vs sclerotherapy (any sclerosant) | no estimate extracted | NR | No studies |
Laser compared to sclerotherapy for treatment of telangiectasias and reticular veins
Population: people with telangiectasias and reticular veins
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Resolution or improvement of telangiectasias ( Laser vs sclerotherapy | no estimate extracted | 5 studies · 593 participants | Moderate Downgraded: imprecision |
Adverse events ‐ hyperpigmentation ( Laser vs sclerotherapy | RR 0.57 [0.4, 0.8] | 4 studies · 262 participants | Moderate Downgraded: imprecision |
Adverse events ‐ matting ( Laser vs sclerotherapy | RR 1 [0.46, 2.19] | 2 studies · 162 participants | Moderate Downgraded: imprecision |
Pain ( Laser vs sclerotherapy | no estimate extracted | 2 studies · 100 participants | Low Downgraded: imprecision |
Recurrence Laser vs sclerotherapy | no estimate extracted | NR | No studies |
Time to resolution Laser vs sclerotherapy | no estimate extracted | NR | No studies |
Quality of life Laser vs sclerotherapy | no estimate extracted | NR | No studies |
Laser plus sclerotherapy compared to sclerotherapy for treatment of telangiectasias and reticular veins
Population: people with telangiectasias and reticular veins
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Resolution or improvement of telangiectasias ( Laser plus sclerotherapy vs sclerotherapy | no estimate extracted | 2 studies · 710 participants | Low Downgraded: inconsistency |
Adverse events ‐ Hyperpigmentation ( Laser plus sclerotherapy vs sclerotherapy | RR 0.83 [0.35, 1.99] | 2 studies · 656 participants | Low Downgraded: inconsistency |
Adverse events ‐ matting ( Laser plus sclerotherapy vs sclerotherapy | RR 0.83 [0.21, 3.28] | 2 studies · 656 participants | Low Downgraded: inconsistency |
Pain ( Laser plus sclerotherapy vs sclerotherapy | RR 2.44 [1.69, 3.55] | 1 study · 596 participants | Low |
Recurrence Laser plus sclerotherapy vs sclerotherapy | no estimate extracted | NR | No studies |
Time to resolution Laser plus sclerotherapy vs sclerotherapy | no estimate extracted | NR | No studies |
Quality of life Laser plus sclerotherapy vs sclerotherapy | no estimate extracted | NR | No studies |
Sclerotherapy (hypertonic glucose plus polidocanol) compared to sclerotherapy (hypertonic glucose)
Population: people with telangiectasias and reticular veins
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Resolution or improvement of telangiectasias ( Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose) | no estimate extracted | 2 studies · 191 participants | Moderate |
Adverse events ‐ hyperpigmentation ( Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose) | RR 0.79 [0.62, 1.01] | 2 studies · 191 participants | Moderate |
Adverse events ‐ matting ( Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose) | RR 0.78 [0.51, 1.2] | 2 studies · 191 participants | Moderate |
Pain ( Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose) | RR 1.02 [0.83, 1.24] | 2 studies · 191 participants | Moderate |
Recurrence Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose) | no estimate extracted | NR | No studies |
Time to resolution Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose) | no estimate extracted | NR | No studies |
Quality of life Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose) | no estimate extracted | NR | No studies |
Sclerotherapy plus compression compared to sclerotherapy alone for telangiectasias and reticular veins
Population: people with telangiectasias and reticular veins
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Resolution or improvement of telangiectasias ( Sclerotherapy plus compression vs sclerotherapy alone | no estimate extracted | 2 studies · 196 participants | Moderate |
Adverse events ‐ hyperpigmentation ( Sclerotherapy plus compression vs sclerotherapy alone | RR 0.93 [0.41, 2.07] | 2 studies · 196 participants | Moderate |
Adverse events ‐ matting ( Sclerotherapy plus compression vs sclerotherapy alone | RR 1.84 [0.17, 19.62] | 1 study · 96 participants | Low |
Pain Sclerotherapy plus compression vs sclerotherapy alone | no estimate extracted | NR | No studies |
Recurrence Sclerotherapy plus compression vs sclerotherapy alone | no estimate extracted | NR | No studies |
Time to resolution Sclerotherapy plus compression vs sclerotherapy alone | no estimate extracted | NR | No studies |
Quality of life ( Sclerotherapy plus compression vs sclerotherapy alone | no estimate extracted | 1 study · 93 participants | Low |